Treatment of Pulmonary Vasculitis

Benjamin Terrier; Loïc Guillevin

doi:10.1055/s-0038-1669414

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2018; 39(04): 504-510
DOI: 10.1055/s-0038-1669414

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Pulmonary Vasculitis

Authors

Benjamin Terrier

¹Department of Internal Medicine, National Referral Center for Rare Systemic and Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France
Loïc Guillevin

²Department of Internal Medicine, Hôpital Cochin, Université Paris, Paris, France

Abstract

Pulmonary vasculitis can be heterogeneous and have some pathophysiological, clinical, and biological specificities that might influence treatment choices. Main vasculitides associated with pulmonary vasculitis include antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, immune complex small vessel vasculitis, and antiglomerular basement membrane disease. Patient characteristics and association of lung involvement with other manifestations affecting disease severity may also influence treatment strategy. Alveolar hemorrhage frequently requires urgent treatment to control the underlying disease and provide supportive care such as mechanical ventilation. The level of evidence of each treatment strategy varies according to the underlying disease, but treatment is usually based on a combination of glucocorticoids and immunosuppressive agents, especially cyclophosphamide and rituximab. The role of plasma exchanges, widely used in patients with severe vasculitis, is controversial, based on results from recent prospective randomized controlled trials.

Keywords

glucocorticoids - cyclophosphamide - rituximab - plasma exchanges - vasculitis - pulmonary vasculitis

Full Text

References

References
1 Guillevin L, Lhote F, Gayraud M. , et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75 (01) 17-28
2 Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. ; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011; 90 (01) 19-27
3 Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) 2010; 62 (08) 1166-1173
4 Robson J, Doll H, Suppiah R. , et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford) 2015; 54 (03) 471-481
5 Stone JH, Merkel PA, Spiera R. , et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363 (03) 221-232
6 Pagnoux C, Quéméneur T, Ninet J. , et al; French Vasculitis Study Group. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol 2015; 67 (04) 1117-1127
7 Puéchal X, Pagnoux C, Baron G. , et al; French Vasculitis Study Group. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheumatol 2017; 69 (11) 2175-2186
8 Walsh M. The effect of plasma exchange on end stage renal disease and death in patients with severe ANCA associated vasculitis. ERA-EDTA Congr. 2018
9 Guillevin L, Cordier JF, Lhote F. , et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40 (12) 2187-2198
10 de Groot K, Harper L, Jayne DR. , et al; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150 (10) 670-680
11 Heijl C, Harper L, Flossmann O. , et al; European Vasculitis Study Group (EUVAS). Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011; 70 (08) 1415-1421
12 Le Guenno G, Mahr A, Pagnoux C, Dhote R, Guillevin L. ; French Vasculitis Study Group. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011; 63 (05) 1435-1445
13 Jones RB, Ferraro AJ, Chaudhry AN. , et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60 (07) 2156-2168
14 Mohammad AJ, Hot A, Arndt F. , et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 2016; 75 (02) 396-401
15 Emmi G, Rossi GM, Urban ML. , et al. Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 2018; 77 (06) 952-954
16 Thiel J, Troilo A, Salzer U. , et al. Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract 2017; 5 (06) 1556-1563
17 Jayne DRW, Gaskin G, Rasmussen N. , et al; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18 (07) 2180-2188
18 De Groot K, Rasmussen N, Bacon PA. , et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52 (08) 2461-2469
19 Jayne DR, Chapel H, Adu D. , et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93 (07) 433-439
20 Martinez V, Cohen P, Pagnoux C. , et al; French Vasculitis Study Group. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008; 58 (01) 308-317
21 Pagnoux C, Mahr A, Hamidou MA. , et al; French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359 (26) 2790-2803
22 Hiemstra TF, Walsh M, Mahr A. , et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs. azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304 (21) 2381-2388
23 Guillevin L, Pagnoux C, Karras A. , et al; French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371 (19) 1771-1780
24 Terrier B, Pagnoux C, Perrodeau É. , et al; French Vasculitis Study Group. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 2018; 77 (08) 1150-1156
25 Charles P, Terrier B, Perrodeau É. , et al; French Vasculitis Study Group. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 2018; 77 (08) 1143-1149
26 Levy J, Pusey CD. Antiglomerular basement membrane disease. In: Warrell DA, Cox TM, Firth JD. , eds. Oxford Textbook of Medicine. New York: Oxford University Press; 2003
27 Touzot M, Poisson J, Faguer S. , et al. Rituximab in anti-GBM disease: a retrospective study of 8 patients. J Autoimmun 2015; 60: 74-79
28 Jordan SC, Lorant T, Choi J. , et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med 2017; 377 (05) 442-453
29 Audemard-Verger A, Pillebout E, Guillevin L, Thervet E, Terrier B. IgA vasculitis (Henoch-Shönlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev 2015; 14 (07) 579-585
30 Audemard-Verger A, Terrier B, Dechartres A. , et al; French Vasculitis Study Group. Characteristics and management of IgA vasculitis (Henoch-Schönlein) in adults: data from 260 patients included in a French Multicenter Retrospective Survey. Arthritis Rheumatol 2017; 69 (09) 1862-1870
31 Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E. ; CESAR study group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int 2010; 78 (05) 495-502
32 Maritati F, Fenoglio R, Pillebout E. , et al. Brief report: rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein). Arthritis Rheumatol 2018; 70 (01) 109-114
33 Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol 2013; 25 (01) 10-18
34 Cacoub P, Lidove O, Maisonobe T. , et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002; 46 (12) 3317-3326
35 Saadoun D, Resche-Rigon M, Thibault V, Piette J-C, Cacoub P. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006; 54 (11) 3696-3706
36 Terrier B, Semoun O, Saadoun D, Sène D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum 2011; 63 (06) 1748-1757
37 Dammacco F, Tucci FA, Lauletta G. , et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116 (03) 343-353
38 Saadoun D, Resche Rigon M, Sene D. , et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116 (03) 326-334 , quiz 504–505
39 Terrier B, Saadoun D, Sène D. , et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009; 60 (08) 2531-2540
40 De Vita S, Quartuccio L, Isola M. , et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64 (03) 843-853
41 Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64 (03) 835-842
42 Terrier B, Krastinova E, Marie I. , et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012; 119 (25) 5996-6004